ZURICH/FRANKFURT, Nov 1 (Reuters) – Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world’s best-selling drug Humira in treating a type of arthritis. The Swiss pharma giant said on Friday that Cosentyx, used in a trial to treat active psoriatic arthritis, yielded “numerically higher results versus Humira” but the statistical readout was not reliable enough to count as evidence. The Swiss group said that Cosentyx, its second-bestselling drug with $2.8 billion in revenue last year, “narrowly missed statistical significance for superiority” over Humira, a drug made by AbbVie.. …read more
Source:: Yahoo Finance
